The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×
CorrectionsFull Access

Corrections

Published Online:

In the article “What Happened to Lithium? Antidepressant Augmentation in Clinical Settings” (Am J Psychiatry 2006; 163:1219–1225), Table 1 (p.1221) contained errors in the presentation and prevalences of antidepressant-antidepressant augmentation strategies. A revised table with an alternate title to more clearly reflect the denominators used for calculating percentages appears below.

Also, in the third paragraph of the Results section, the second and third sentences should read as follows: “Bupropion and sertraline were the most frequently appearing antidepressants in combined antidepressant augmentation strategies. Bupropion appeared in 10,279 (38%) of all antidepressant-antidepressant combinations and sertraline appeared in 6,727 (25%).”